文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

血管生成、代谢与免疫检查点生物标志物的动态分析可预测腹腔脓毒症患者的慢性危重症及长期结局

Dynamic Profiling of Angiogenic, Metabolic, and Immune Checkpoint Biomarkers Predicts Chronic Critical Illness and Long-term Outcomes in Abdominal Sepsis.
PubMed 文献 · Shock · 2026-03-03
一句话结论腹腔脓毒症患者诊断后第4天联合临床变量与关键生物标志物可较强预测慢性危重症(AUC=0.926),第7天可预测1年不良功能结局(AUC=0.910)。

本研究为前瞻性纵向研究,纳入252例成人腹腔脓毒症患者,在诊断后第1、4、7、14天检测13种血清生物标志物,比较快速康复组与慢性危重症(CCI)组的动态变化。CCI组持续存在免疫抑制标志物(可溶性程序性死亡配体1、精氨酸酶-1、转化生长因子-β)和炎症标志物(诱导蛋白-10)升高,以及血管生成和代谢通路失调。基于易感性、损伤、反应和器官功能障碍框架的临床变量模型预测第4天CCI的AUC为0.899,预测第7天1年不良结局(Zubrod 4/5)的AUC为0.851;加入关键生物标志物后,预测CCI的AUC提升至0.926,预测功能结局的AUC提升至0.910。作者认为持续炎症-免疫抑制-分解代谢综合征在腹腔脓毒症后CCI发生中起核心作用,系列生物标志物联合临床变量有助于更早、更准确地进行风险分层。

要点

  • 腹腔脓毒症诊断后第4天,联合PIR O临床变量与关键生物标志物预测CCI的AUC达0.926,优于单纯临床变量(AUC=0.899)。
  • 诊断后第7天联合模型预测1年不良功能结局(Zubrod 4/5)的AUC为0.910,优于单纯临床变量(AUC=0.851)。
  • CCI患者持续存在免疫抑制标志物(sPD-L1、精氨酸酶-1、TGF-β)和炎症标志物(IP-10)升高,并伴血管生成与代谢通路失调。
  • 传统SOFA和APACHE II评分不能有效识别高危CCI轨迹患者,限制了早期干预机会。

适用人群与场景

  • 在一家三级急性照护中心诊断为腹腔脓毒症的成人患者,前瞻性纵向研究纳入252例。

诊断标准与关键阈值

  • 患者分为快速康复(RAP)组和慢性危重症(CCI)组,CCI以ICU停留延长、持续器官功能障碍和1年结局差为特征。
  • 1年不良功能结局定义为Zubrod评分4/5。

研究设计与关键结果

  • 研究为前瞻性纵向研究,纳入252例成人腹腔脓毒症患者,在诊断后第1、4、7、14天检测13种血清生物标志物。
  • CCI患者较RAP患者临床结局更差,持续存在免疫抑制标志物(sPD-L1、精氨酸酶-1、TGF-β)和炎症标志物(IP-10)升高,以及血管生成和代谢通路失调。
  • 基于PIR O变量(易感性、损伤、反应、器官功能障碍)的多变量模型预测第4天CCI的AUC=0.899,预测第7天1年不良结局(Zubrod 4/5)的AUC=0.851。
  • 加入关键生物标志物后,预测CCI的AUC提升至0.926,预测功能结局的AUC提升至0.910。

证据类型、等级与局限

  • 证据类型:前瞻性纵向研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,系列生物标志物数据联合临床变量可实现更早、更准确的风险分层,可能支持及时、有针对性的干预以改善患者生存和长期康复。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Many patients who survive abdominal sepsis develop Chronic Critical Illness (CCI), characterized by prolonged intensive care unit stay, ongoing organ dysfunction, and poor 1-year outcomes. Current severity scoring systems, such as Sequential Organ Failure Assessment and Acute Physiology and Chronic Health Evaluation II, are not effective in identifying patients at high risk for this trajectory, limiting the opportunities for early intervention.

METHODS: We conducted a prospective longitudinal study of adults diagnosed with abdominal sepsis at a tertiary acute care center. The serum levels of 13 biomarkers were measured on days 1, 4, 7, and 14 after diagnosis. Patients were grouped into two categories: Rapid Recovery (RAP) and CCI. Predictive models were developed by combining clinical data based on the Predisposition, Insult, Response, and Organ dysfunction framework with biomarker trends to assess the evolving host response.

RESULTS: Patients with CCI showed poorer clinical outcomes than those with RAP. Among the 252 patients included in the analysis, dynamic profiling revealed significant differences between the RAP and CCI groups. Patients who developed CCI exhibited persistently elevated levels of immunosuppressive biomarkers (soluble programmed death-ligand 1, arginase-1, and transforming growth factor-beta) and inflammatory markers (induced protein-10), along with dysregulation of the angiogenic and metabolic pathways. Multivariate models incorporating Predisposition, Insult, Response, and Organ dysfunction variables showed strong performance in predicting CCI by day 4 (area under the curve [AUC] = 0.899) and poor 1-year outcomes (Zubrod 4/5) by day 7 (AUC = 0.851). The addition of key biomarkers significantly enhanced the predictive accuracy for both CCI (AUC = 0.926) and functional outcomes (AUC = 0.910).

CONCLUSIONS: Our findings suggest that Persistent Inflammation, Immunosuppression, and Catabolism Syndrome, a maladaptive pathophysiological state, plays a central role in the development of CCI after abdominal sepsis. The combination of serial biomarker data and clinical variables enables earlier and more accurate risk stratification. This approach may support timely and targeted interventions to improve patient survival and long-term recovery.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Xu T, Lin C, Huang H, et al. Dynamic Profiling of Angiogenic, Metabolic, and Immune Checkpoint Biomarkers Predicts Chronic Critical Illness and Long-term Outcomes in Abdominal Sepsis. Shock. 2026. PMID: 41886625. doi:10.1097/SHK.0000000000002829

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。